NIH ends trial of Eli Lilly COVID-19 antibody treatment among hospitalized patients
The U.S. National Institutes of Health on Monday ended one clinical trial of Eli Lilly's experimental COVID-19 antibody treatment after finding that the drug, "bamlanivimab, is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease." The trial was suspended Oct. 13 out of "an abundance of caution," but the NIH said Monday it had found no significant safety issue with the monoclonal antibody treatment.
Eli Lilly said it will continue testing bamlanivimab with the NIH on mild or moderately ill COVID-19 patients to see if it reduces hospitalizations and severe symptoms. Eli Lilly is also conducting its own separate trials.
Human bodies make antibodies to fight off infections, and Eli Lilly's experimental drug, like a similar treatment from Regeneron, features concentrated copies of one or two antibodies found to be effective at fighting of COVID-19. President Trump was given Regeneron's version when he was hospitalized with COVID-19, and public health experts have high hopes for monoclonal antibody treatments. Eli Lilly and Regeneron are both seeking emergency use authorization from the Food and Drug Administration.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Today's political cartoons - November 24, 2024
Cartoons Sunday's cartoons - taped bananas, flying monkeys, and more
By The Week US Published
-
The Spanish cop, 20 million euros and 13 tonnes of cocaine
In the Spotlight Óscar Sánchez Gil, Chief Inspector of Spain's Economic and Tax Crimes Unit, has been arrested for drug trafficking
By The Week UK Published
-
5 hilarious cartoons about the rise and fall of Matt Gaetz
Cartoons Artists take on age brackets, backbiting, and more
By The Week US Published
-
US charges Indian tycoon with bribery, fraud
Speed Read Indian billionaire Gautam Adani has been indicted by US prosecutors for his role in a $265 million scheme to secure solar energy deals
By Peter Weber, The Week US Published
-
Boeing machinists approve contract, end strike
Speed Read The company's largest union approved the new contract offer, ending a seven-week strike
By Peter Weber, The Week US Published
-
US economy still strong in final preelection report
Speed Read It grew at a solid 2.8% annual rate from July through September
By Peter Weber, The Week US Published
-
Boeing machinists reject deal, continue strike
Speed Read The rejection came the same day Boeing reported a $6.2 billion quarterly loss
By Peter Weber, The Week US Published
-
Ports reopen after dockworkers halt strike
Speed Read The 36 ports that closed this week, from Maine to Texas, will start reopening today
By Peter Weber, The Week US Published
-
Empty-nest boomers aren't selling their big homes
Speed Read Most Americans 60 and older do not intend to move, according to a recent survey
By Peter Weber, The Week US Published
-
Brazil accuses Musk of 'disinformation campaign'
Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
By Rafi Schwartz, The Week US Published
-
Disney board fends off Peltz infiltration bid
Speed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
By Rafi Schwartz, The Week US Published